Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...
Obesity
Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France
French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...
Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets
Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio...
Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output
Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia
Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...
Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...
Belgium Bans Ozempic for Weight Loss as Global Shortage Persists
Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...
Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004
Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant...
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing...
Innovent Biologics’ Mazdutide Shows Promising Weight Loss Results in Phase II Trial
China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight...
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...
Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases
Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...